Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
23191 | 300 | 40.4 | 91% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
389 | 16325 | RHEUMATOID ARTHRITIS//RHEUMATOLOGY//RHEUMATOL |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | ANTI TNF ALPHA THERAPIES | Author keyword | 2 | 67% | 1% | 2 |
2 | GENHOTEL RECH EUROPEEN POLYARTHRITE RHUMATOID | Address | 2 | 67% | 1% | 2 |
3 | PATHOL RHEUMATOL | Address | 2 | 67% | 1% | 2 |
4 | TNFR II | Author keyword | 2 | 67% | 1% | 2 |
5 | UNITE MIXTE HOSPICES CIVILS LYON BIOMERIEUX | Address | 2 | 67% | 1% | 2 |
6 | ECRAF | Address | 2 | 50% | 1% | 3 |
7 | MOL IMMUNOGENET GRP | Address | 2 | 18% | 3% | 8 |
8 | GRP RECERCA REUMATOL | Address | 1 | 40% | 1% | 2 |
9 | IIS LA PRINCESA | Address | 1 | 40% | 1% | 2 |
10 | TNF ALPHA 308 POLYMORPHISM | Author keyword | 1 | 40% | 1% | 2 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | TNF ALPHA 308 G A POLYMORPHISM | 14 | 100% | 2% | 7 |
2 | POSITION 308 | 5 | 54% | 2% | 7 |
3 | P55 GENE | 4 | 56% | 2% | 5 |
4 | ALPHA BLOCKING AGENTS | 4 | 35% | 3% | 9 |
5 | 676T GREATER THAN G POLYMORPHISM | 3 | 100% | 1% | 3 |
6 | ANTI TNF TREATMENT | 3 | 31% | 3% | 8 |
7 | FACTOR RECEPTOR II | 2 | 23% | 2% | 7 |
8 | INTERFERON SIGNATURE | 1 | 31% | 1% | 4 |
9 | HUMAN AUTOIMMUNE DISEASE | 1 | 38% | 1% | 3 |
10 | M196R POLYMORPHISM | 1 | 100% | 1% | 2 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Tumour necrosis factor alpha-308G -> A polymorphism is not associated with response to TNF alpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis | 2010 | 39 | 32 | 66% |
Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response | 2011 | 46 | 79 | 41% |
Gene expression analysis in RA: towards personalized medicine | 2014 | 10 | 153 | 24% |
Current and future trends in biomarker discovery and development of companion diagnostics for arthritis | 2015 | 2 | 121 | 21% |
The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis | 2013 | 8 | 43 | 35% |
Biomarkers for prediction of TNF alpha blockers response in rheumatoid arthritis | 2010 | 14 | 55 | 58% |
Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis | 2015 | 1 | 102 | 30% |
Pharmacogenomics of biological treatment in rheumatoid arthritis | 2014 | 2 | 49 | 49% |
Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature | 2011 | 12 | 38 | 53% |
Genetic and genomic predictors of anti-TNF response | 2011 | 18 | 81 | 40% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | GENHOTEL RECH EUROPEEN POLYARTHRITE RHUMATOID | 2 | 67% | 0.7% | 2 |
2 | PATHOL RHEUMATOL | 2 | 67% | 0.7% | 2 |
3 | UNITE MIXTE HOSPICES CIVILS LYON BIOMERIEUX | 2 | 67% | 0.7% | 2 |
4 | ECRAF | 2 | 50% | 1.0% | 3 |
5 | MOL IMMUNOGENET GRP | 2 | 18% | 2.7% | 8 |
6 | GRP RECERCA REUMATOL | 1 | 40% | 0.7% | 2 |
7 | IIS LA PRINCESA | 1 | 40% | 0.7% | 2 |
8 | SECT MUSCULOSKELETAL SCI | 1 | 17% | 1.3% | 4 |
9 | FEDERATIF RECH MULTIDISCIPLINAIRE PEPTIDES 2 | 1 | 21% | 1.0% | 3 |
10 | BIOMED MED PHARM | 1 | 50% | 0.3% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000194971 | ABATACEPT//TOCILIZUMAB//DISEASE MODIFYING ANTIRHEUMATIC DRUGS |
2 | 0.0000191484 | TNF ALPHA GENE POLYMORPHISM//MOL LIFESCI//VA NEGOVSKY GEN REANIMATOL |
3 | 0.0000183554 | HANS WILSDORF//CLIN IMMUNOL UNITHANS WILSDORF//IMMUNOL ALLERGYCLIN IMMUNOL UNIT |
4 | 0.0000181145 | CIBER BBN SALUD CARLOS 3//RIER RED INFLAMAC ENFERMEDADES REUMAT//PROTEORED ISCIII PROTE GRP |
5 | 0.0000171083 | PTPN22//PROTEIN TYROSINE PHOSPHATASE NONRECEPTOR 22//IRF5 |
6 | 0.0000152227 | FIBROBLAST LIKE SYNOVIOCYTES//BEREICH MOL MED MUSKULOSKELETALEN SYST//ABORATING MOL BIOL NOVEL THER EUT STRA |
7 | 0.0000134913 | MERIEUX//BLOOD TRANSCRIPTOME//DUTCH NUTRIGENOM CONSORTIUM |
8 | 0.0000108189 | SHARED EPITOPE//HLA DRB1//HLA DR4 |
9 | 0.0000104098 | UNC93B1//MARY KIRKLAND LUPUS//TLR7 |
10 | 0.0000096291 | PALINDROMIC RHEUMATISM//RECURRENT ARTHRITIS//INTERMITTENT HYDRARTHROSIS |